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Background: Pulmonary rehabilitation improves functional capacity and symptoms in the inter-
stitial lung diseases (ILDs), however there is marked variation in outcomes between individ-
uals. The aim of this study was to establish the impact of the aetiology and severity of ILD
on response to pulmonary rehabilitation.
Methods: Forty-four subjects with ILD, including 25 with idiopathic pulmonary fibrosis (IPF),
underwent eight weeks of pulmonary rehabilitation. Relationships between disease aetiology,
markers of disease severity and response to pulmonary rehabilitation were assessed after eight
weeks and six months, regardless of program completion.
Results: In IPF, greater improvements in 6-minute walk distance (6MWD) immediately
following pulmonary rehabilitation were associated with larger forced vital capacity
(r Z 0.49, p Z 0.01), less exercise-induced oxyhaemoglobin desaturation (rS Z 0.43,
p Z 0.04) and lower right ventricular systolic pressure (r Z 0.47, p Z 0.1). In participants
with other ILDs there was no relationship between change in 6MWD and baseline variables. Less
exercise-induced oxyhaemoglobin desaturation at baseline independently predicted a larger
improvement in 6MWD at six month follow-up. Fewer participants with IPF had clinically impor-
tant reductions in dyspnoea at six months compared to those with other ILDs (25% vs 56%,distance; CRQ, Chronic Respiratory Questionnaire; DLCO, diffusing capacity for carbon monoxide;
rstitial lung disease; IPF, idiopathic pulmonary fibrosis; MID, minimal important difference; ROC,
P, right ventricular systolic pressure; SpO2, oxyhaemoglobin saturation measured by pulse oximetry.
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430 A.E. Holland et al.p Z 0.04). More severe dyspnoea at baseline and diagnosis other than IPF predicted greater
improvement in dyspnoea at six months.
Conclusions: Patients with IPF attain greater and more sustained benefits from pulmonary
rehabilitation when disease is mild, whereas those with other ILDs achieve benefits regardless
of disease severity. Early referral to pulmonary rehabilitation should be considered in IPF.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
The interstitial lung diseases (ILDs) are characterised by
distressing dyspnoea, progressive deterioration in exercise
tolerance, poor health-related quality of life and reduced
life expectancy. Emerging evidence suggests pulmonary
rehabilitation programs that include exercise training may
improve functional capacity and symptoms.1,2 However,
the impact of pulmonary rehabilitation on these outcomes
is smaller and less consistent than that observed in other
populations.3 This may contribute to the poor uptake of this
treatment noted in clinical practice.4
Preliminary evidence suggests that response to pulmo-
nary rehabilitation may vary according to diagnosis. Data
from a systematic review suggest that patients with idio-
pathic pulmonary fibrosis (IPF) exhibit a smaller exercise
response to pulmonary rehabilitation than those with other
ILDs and may not achieve symptomatic benefit.5 However,
this could reflect the impact of more severe disease on
exercise responses,6e8 rather than an effect of IPF itself. To
date no studies have evaluated the independent effects of
diagnosis and disease severity on response to pulmonary
rehabilitation in ILD.
There are few treatment options for many patients with
ILD and as a result there is increasing interest in treatments
such as pulmonary rehabilitation, which may relieve
symptoms without changing disease course.9,10 There are
no guidelines recommending when pulmonary rehabilita-
tion should be offered, although it has been suggested that
patients should be referred early in the disease.11 We
hypothesised that (1) in IPF, participants with less severe
disease achieve larger and more sustained benefits from
pulmonary rehabilitation; and (2) pulmonary rehabilitation
is effective across the disease spectrum in those with non-
IPF ILDs.
Methods
Patients with documented ILD were recruited from two
tertiary hospitals between January 2007 and December
2008. Diagnostic criteria for IPF were consistent with the
International Consensus Statement.12 Patients were eligible
to participate if they were ambulant and reported dysp-
noea on exertion on stable medical therapy. Exclusion
criteria were a history of syncope on exertion; any comor-
bidities precluding exercise training; or participation in
a pulmonary rehabilitation program in the last two years.
Participants were consecutive patients who were assessed
as suitable for rehabilitation by their treating doctor and
referred to the rehabilitation program. Some (n Z 9) wereparticipants in a study investigating the minimum important
difference (MID) for the 6MWD in ILD.13 All participants gave
written informed consent and the study was approved by
the human ethics committees at both sites.
All participants took part in a twice-weekly eight-week
exercise training program of endurance and strength
training which was prescribed and progressed according to
a previously described standardised protocol.1 Supple-
mental oxygen was provided as required to maintain oxy-
haemoglobin saturation (SpO2) 85%. An unsupervised
home exercise programme was also prescribed with the aim
of achieving five exercise sessions per week in total. Those
participants who had been prescribed supplemental oxygen
(n Z 17) were instructed to use this during home exercise.
Participants were encouraged to record their home exer-
cise in a diary, which was reviewed weekly by the treating
clinician. Participants also attended an education and self-
management program. At program completion participants
were encouraged to continue exercising at least three
times per week.
Baseline measurements included spirometry, diffusing
capacity (DLCO) and trans-thoracic echocardiogram. Lung
function tests were repeated immediately after the inter-
vention and at six months.
Outcomes were assessed in all participants, regardless of
programcompletion, at baseline, eightweeks and sixmonths
by an independent assessor who was not involved in delivery
of pulmonary rehabilitation. Functional exercise capacity
was assessed using the 6-minute walk test (6MWT).14 Use of
oxygen during the test was standardised and the test was
stopped if SpO2 fell below 80%, in accordance with a previ-
ously described protocol for ILD.15 Follow-upwalk tests were
conducted using the same flow rate of supplemental oxygen
as at baseline. Distance walked in six minutes (6MWD) and
lowest SpO2 were recorded. Impact of pulmonary rehabili-
tation on symptoms was measured using the Chronic Respi-
ratory Questionnaire (CRQ) dyspnoea domain.16
The aim of this study was to determine predictors of long-
term response to pulmonary rehabilitation in ILD. Primary
endpoints for long-term response were defined as: (1)
exercise response e change in 6MWD from baseline to six
months; and (2) symptom response e change in CRQ dysp-
noea domain from baseline to six months. Short-term
responses were considered as secondary outcomes, and
were defined by comparing the same outcomes at baseline
and program completion. The proportion of participants
achieving gains exceeding the MID for 6MWD and CRQ dysp-
noea, calculated at program completion and at six months,
were also secondary endpoints. The MID for 6MWD and CRQ
dyspnoea domainwere defined as a change of greater than or
equal to 34 m13 and 2.5 points17 respectively.
Pulmonary rehabilitation for interstitial lung disease 431Potential physiological markers which may impact on
response to pulmonary rehabilitation were defined a priori,
based on previously documented markers of disease
severity and prognosis in IPF.18e20 These were forced vital
capacity (FVC), DLCO, resting right ventricular systolic
pressure (RSVP) and nadir SpO2 on baseline 6-minute walk
test. Baseline 6MWD was also included in the analysis of
exercise response as this was associated with response to
pulmonary rehabilitation in a retrospective study,21 while
baseline dyspnoea was included in the analysis of symptom
response. Change in TLCO over six months was included in
the analysis of long-term response to evaluate the effects
of disease progression.Sample size
The pre-specified sample size was 44 participants. This
study was powered to detect an association between
change in 6MWD following rehabilitation (the dependent
variable) and markers of disease severity and prognosis
(independent variables). To detect a relationship between
baseline DLCO and change in 6MWD with 80% power, 22
subjects with IPF were required. This was based on pilot
data which suggested a reduction in 6MWD response to
rehabilitation for IPF participants of 1.6 m for every unit
reduction in DLCO at baseline, assuming standard devia-
tions of 20.6 for DLCO and 54 m for change in 6MWD.
Numbers required to assess the relationship between
change in 6MWD and FVC, right ventricular systolic pressure
(RVSP) and total lung capacity (TLC) were 18, 16 and 15
subjects respectively. An equivalent number of participants
with non-IPF ILDs was recruited as a comparator group,
matched for disease severity using FVC and DLCO.Table 1 Baseline demographic characteristics of partici-






Age, years 72.9 (6.8) 68.1 (8.4) 0.05
FVC, %predicted 76.4 (20.3) 72.1 (23.6) 0.53
TLCO, %predicted 48.5 (19.1) 51.7 (19.3) 0.48
TLC, %predicted 74.9 (16.7) 73.2 (16.2) 0.79
RVSP, mmHg 36.5 (15.7) 36.0 (11.4) 0.93
6MWD, m 370 (127) 411 (96) 0.24
Nadir SpO2, % 85 (7) 88 (5) 0.13
CRQ dyspnoea 15.3 (3.8) 16.5 (5.6) 0.42
Data are mean (standard deviation); p value is comparison
between IPF and other ILDs. FVC forced vital capacity; TLCO e
diffusing capacity for carbon monoxide; TLC e total lung
capacity; RVSP e right ventricular systolic pressure on trans-
thoracic echocardiogram; 6MWD e 6-minute walk distance;
nadir SpO2 e oxyhaemoglobin saturation on baseline 6-minute
walk test; CRQ e Chronic Respiratory Questionnaire.Statistical analysis
The effects of pulmonary rehabilitation on exercise toler-
ance and dyspnoea in IPF and non-IPF groups were evalu-
ated using repeated measures analysis of variance. The
number of participants in IPF and non-IPF groups who
achieved benefits exceeding the MID for 6MWD and CRQ
dyspnoea was compared using the Pearson Chi Square test.
Stepwise multiple linear regression analysis was undertaken
to identify independent predictors of 6-month outcome,
using change in 6MWD and CRQ dyspnoea domain as
dependent variables and diagnosis (IPF or other ILD) as
a categorical independent variable. In order to select
baseline variables for inclusion in the model, relationships
between response to rehabilitation and baseline predictor
variables were assessed with Pearson’s r or with Spearman’s
rho (rS) as appropriate. Baseline variables with a univariate
relationship to the dependent variable (p  0.1) were
entered into the model. Variables that were not significant
were removed from the model. For continuous variables,
receiver operating characteristic (ROC) curves were used to
identify thresholds that discriminated responders from non-
responders. A p < 0.05 was considered statistically signifi-
cant. All analyses were undertaken using SPSS version 17.0
(SPSS Inc, Chicago, IL).Results
Forty-four participants were recruited, 25 of whom had IPF
(Table 1). Participants with other ILDs had diagnoses of
sarcoidosis (n Z 3), hypersensitivity pneumonitis (n Z 5),
non-specific interstitial pneumonia (n Z 3), asbestosis
(nZ 5) and connective tissue disease (nZ 3). Participants
with IPF were well matched for disease severity to those
with other ILDs but tended to be younger. Six participants
did not complete the rehabilitation program, due to
respiratory illness (n Z 1), other illness (n Z 1), musculo-
skeletal pain (nZ 1) and lack of motivation (nZ 3). Two of
these participants, both with IPF, declined further partici-
pation in the study. Diary data indicated that the partici-
pants completed 77% of the expected home exercise
sessions. One participant was too unwell to complete the 6-
minute walk test at 6-months follow-up due to progression
of IPF; this participant completed the questionnaires only.
One participant with IPF died prior to 6-month follow-up.
Data were available for 42 participants immediately
following the program and 41 participants at six months.
Respiratory function tended to be reduced at six months
but this did not reach statistical significance for either FVC
(mean e 60ml, 95% confidence interval e 163e45 ml) or
DLCO (0.74 ml/min/mmHg, 2.1e0.62 ml/min/mmHg).
Reduction in DLCO tended to be greater in participants with
IPF but this did not reach statistical significance (pZ 0.27).
The 6MWD improved significantly following the program
in both IPF and non-IPF groups, however this effect was no
longer evident at six months (Fig. 1). The mean improve-
ment in 6MWD for participants with IPF at program
completion was 21 (58) m (mean, standard deviation)
compared to 43 (56) m in those with other ILDs (pZ 0.21).
Improvements in 6MWD that exceeded the MID occurred in
40% of those with IPF, compared to 52% of those with other
ILDs (pZ 0.41). After six months 35% of those with IPF had
maintained gains in 6MWD that exceeded the MID,
compared to 41% of the non-IPF group (p Z 0.68).
Figure 1 Comparison of exercise response to pulmonary
rehabilitation in participants with IPF and other ILDs. IPF e
idiopathic pulmonary fibrosis, 6MWD e 6-minute walk distance.
)p < 0.05 vs baseline for both groups.
432 A.E. Holland et al.Dyspnoea improved immediately following pulmonary
rehabilitation, with a mean improvement of 2.7(5.6) points
in those with IPF compared to 4.6 (5.2) points in those with
other ILDs (p Z 0.25, Fig. 2). No effect on dyspnoea was
evident after six months. At program completion 59% of
those with IPF achieved improvements in dyspnoea that
exceeded the MID, compared to 67% of those with other
ILDs (p Z 0.62). After six months a significantly lower
proportion of those with IPF had clinically important
improvements in dyspnoea (24% vs 56%, p Z 0.04).
There were no significant associations between baseline
characteristics and improvement in 6MWD when the entire
group was analysed together either at program completion
(n Z 42) or six months later (n Z 41). However, in partic-
ipants with IPF, univariate analysis suggested that larger
changes in 6MWD immediately following rehabilitation were
associated with a greater FVC, lower RVSP and less oxy-
haemoglobin desaturation on baseline 6MWD (Table 2).Figure 2 Comparison of symptoms response to pulmonary
rehabilitation in participants with IPF and other ILDs. IPF e
idiopathic pulmonary fibrosis, CRDQ e chronic respiratory
disease questionnaire. )p < 0.05 vs baseline for both groups.Similar relationships were seen at six months, with the
exception of RVSP. In those with other ILDs, baseline
characteristics had no relationship to exercise response at
either timepoint. In a stepwise multiple regression model
that included nadir SpO2 on baseline 6-minute walk test and
baseline FVC, the only significant predictor of long-term
exercise response was nadir SpO2 (Table 3). This model
explained 18% of the variation in exercise response at six
months. Nadir SpO2 was also the best predictor of short-
term exercise response, however this model did not reach
statistical significance (p Z 0.08). Post-hoc analysis using
the ROC curve method indicated that a SpO2 threshold of
86% differentiated long-term 6MWD responders from non-
responders with a sensitivity of 80%, however specificity
was 56% and the area under the curve was 64%.
There were no significant associations between baseline
physiology and change in dyspnoea immediately after the
pulmonary rehabilitation program, either in the group as
a whole or in subgroups of IPF and non-IPF participants.
However, those with worse baseline dyspnoea had signifi-
cantly greater improvements in dyspnoea at six months,
both for IPF and non-IPF groups (Table 2). In a stepwise
multiple regression model, the baseline CRQ dyspnoea
score and a diagnosis of IPF were predictors of symptom
response at six months (Table 4). This model explained 43%
of the variation in symptom response at six months, with
IPF participants less likely to achieve improvements (Table
4). This model explained 31% of the variation in symptom
response at six months. Post-hoc analysis could not identify
a suitable threshold for baseline CRQ dyspnoea score to
predict long-term symptom outcome.Discussion
This study is the first to prospectively evaluate predictors of
long-term benefit from pulmonary rehabilitation in people
with IPF and other ILDs using an intention-to-treat analysis.
Improvements in functional exercise capacity for people
with IPF were related to markers of disease severity and
prognosis, with greatest and most sustained treatment
effects achieved in those with milder disease. In contrast,
people with other ILDs attain benefits from pulmonary
rehabilitation regardless of disease severity and are more
likely than those with IPF to achieve sustained reductions in
dyspnoea.
Consistent with previous reports, there was a significant
improvement in 6MWD following pulmonary rehabilitation
in both IPF and non-IPF groups.1,2,21e23 However there was
marked variability in response between individuals and only
a minority of participants with IPF achieved the MID. Our
data indicate that this may be explained by disease
severity, with greater gains evident in those with a higher
FVC %predicted and less exercise-induced desaturation.
Similarly, a recent study in IPF found short-term benefits of
pulmonary rehabilitation occurred only in less disabled
participants.24 In a previous retrospective study21 there was
no relationship between improvement in 6MWD and disease
severity in a large group with mixed ILDs. This is consistent
with our results, where the relationship between response
to pulmonary rehabilitation and markers of disease severity
only became evident when the subgroup of patients with
Table 2 Relationship between baseline characteristics and response to pulmonary rehabilitation.
Short-term response Long-term response
Change in 6MWD Change in CRQ
dyspnoea
Change in 6MWD Change in CRQ
dyspnoea
IPF Non-IPF IPF Non-IPF IPF Non-IPF IPF Non-IPF
FVC %pred 0.49* 0.07 0.01 0.09 0.40y 0.16 0.04 0.26
DLCO %pred 0.29 0.31 0.03 0.26 0.08 0.05 0.06 0.34
RVSP, mmHg 0.47y 0.03 0.42 0.33 0.18 0.09 0.006 0.21
Nadir SpO2, % 0.43* 0.21 0.16 0.14 0.55* 0.02 0.29 0.21
Baseline 6MWD, m 0.20 0.39 0.18 0.14 0.31 0.28 0.03 0.07
Baseline CRQ dyspnoea 0.25 0.12 0.34 0.39 0.08 0.17 0.52* 0.60*
Data are Pearson’s r, except for short-term 6MWD response in non-IPF which are Spearman’s rho. yp < 0.1, *p < 0.05.
FVC forced vital capacity; TLCO e diffusing capacity for carbon monoxide; TLC e total lung capacity; RVSP e right ventricular systolic
pressure on trans-thoracic echocardiogram; 6MWD e 6-minute walk distance; nadir SpO2 e oxyhaemoglobin saturation on baseline 6-
minute walk test; CRQ e Chronic Respiratory Questionnaire.
Pulmonary rehabilitation for interstitial lung disease 433IPF was analysed separately. The current study suggests
that accurate diagnostic information may assist with
appropriate referral to pulmonary rehabilitation in ILD.
Although the natural history of IPF is unpredictable, the
majority of patients experience a gradual decline in
pulmonary function over many years.25 Our data suggest
that for such patients, early referral to pulmonary reha-
bilitation may be required in order to maximise its benefits.
A smaller degree of exercise-induced desaturation was
the only independent predictor of exercise benefits at six
months following the pulmonary rehabilitation program.
Desaturation on 6-minute walk test has a strong relation-
ship to other markers of disease severity in IPF, including
FVC,26 and thus other markers of disease severity were not
retained in the model. Diagnosis of IPF did not remain an
independent predictor of response when desaturation was
included, suggesting that the effect of IPF on exercise
response is mediated by the degree of desaturation during
exercise.27 This is supported by the greater degree of
desaturation evident in participants with IPF, despite
matching for other measures of disease severity (Table 1)
and likely reflects the greater degree of gas exchange
impairment during exercise.28 It is possible that greater
desaturation during exercise may limit the training inten-
sity that can be achieved in pulmonary rehabilitation,
resulting in less favourable outcomes for IPF participants,
however this has not yet been tested. It should be noted
that our model explained only a small proportion of the
variance in 6MWD, suggesting that other unidentified
factors also contribute to longer-term outcomes. Post-hoc
analysis indicated that a nadir SpO2 during the 6-minuteTable 3 Stepwise multiple linear regression model for change
rehabilitation.
B SE of B
Constant 496.456 179.601
Nadir SpO2 at baseline 5.699 2.058
R2 for model
6MWD e 6-minute walk distance; nadir SpO2 e lowest oxyhaemoglob
coefficient; SE standard error; R2 e proportion of variation in changewalk test of 86% or less could distinguish responders from
non-responders; however an area under the curve of only
0.64 suggests that caution should be exercised in applying
this threshold to clinical practice.
Sustained improvements in dyspnoea following pulmo-
nary rehabilitation were significantly more likely in non-IPF
participants with worse dyspnoea scores at baseline.
Although short-term improvements in dyspnoea have previ-
ously been documented in randomised controlled trials1 and
observational studies,23 longer-term gains following reha-
bilitation have not been demonstrated.5,22 These data indi-
cate that dyspnoeic patients with non-IPF ILDs are more
likely than those with IPF to achieve long-term symptomatic
benefit from pulmonary rehabilitation, with significant
improvements in dyspnoea still evident in over half of the
non-IPF participants at six months following the program. To
our knowledge this is the first report of sustained benefits
following pulmonary rehabilitation for ILD. These results are
encouraging for a patient group with few treatment options.
Further investigation of these effects in a randomised
controlled trial is warranted.
Many patients with IPF are not routinely referred to
pulmonary rehabilitation as physicians feel that its benefits
are unproven.4 Existing randomised controlled trials are
small1,2 and no previous prospective study has evaluated
predictors of response related to diagnosis and disease
severity. Only low grade recommendations regarding exer-
cise training for ILD are provided in guidelines for clinical
practice in pulmonary rehabilitation29 and ILD25,30. This
may be due in part to lack of certainty regarding which
patients will benefit and how long any positive effects willin 6MWD from baseline to six months following pulmonary




in saturation on baseline 6-minute walk test; B e unstandardised
in 6MWD at six months explained by the model.
Table 4 Stepwise multiple linear regression model for change in dyspnoea from baseline to six months following pulmonary
rehabilitation.
B SE of B Standardised beta p value
Constant 16.655 4.048 0.001
CRDQ dyspnoea score at
baseline
0.776 0.2189 0.518 0.001
IPF diagnosis 4.442 1.960 0.328 0.031
R2 for model 31%
CRDQ e chronic respiratory disease questionnaire; B e unstandardised coefficient; SE e standard error; R2 e proportion of variation in
change in CRDQ score explained by the model.
434 A.E. Holland et al.last. Data from the current study confirm the clinically
important effects of pulmonary rehabilitation for patients
across the spectrum of ILDs and indicate that for patients
with IPF, the timing of treatment matters. Our results
support the contention of previous authors that pulmonary
rehabilitation should be considered the standard of care for
people with ILD21 and add evidence supporting early
referral for patients with IPF.
Weaknesses of this study include the relatively small
numbers of participants and the small number of predictors
evaluated. However, the study was adequately powered to
assess relationships of interest which were specified a pri-
ori. Only small numbers of independent variables were
included in the regression models to ensure stability of the
estimates. Our study numbers compare favourably with
recently published prospective studies in this area.1,2,22,23
Strengths of this study are its prospective design and the
use of intention-to-treat analysis, making the likelihood of
overestimation of treatment effect low. An additional
strength is the inclusion of a six month follow-up period,
providing data regarding the sustained effects of pulmonary
rehabilitation.
In conclusion, this study demonstrates that patients with
IPF have greater improvements in functional exercise
capacity when pulmonary rehabilitation is delivered early
in the course of disease. Patients with other ILDs achieve
significant gains in exercise capacity regardless of disease
severity and are more likely than those with IPF to achieve
sustained improvements in dyspnoea. Admission criteria for
pulmonary rehabilitation programs should support the
inclusion of patients with ILD and facilitate early partici-
pation in those with IPF.Conflict of interest
The authors have no conflicts of interest to declare in
relation to this work.References
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